Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion type Assertion NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_head.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion description "[Recently, the nonpeptide bradykinin (BK) antagonist 2,3,4,5,6-pentafluorocinnamoyl-(o-2,6-dichlorobenzyl)-l-tyrosine-N-(4-amino-2,2,6,6-tetramethyl-piperidyl) amide (BKM-570) was shown to cause impressive growth inhibition of lung and prostate tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_provenance.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion evidence source_evidence_literature NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_provenance.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion SIO_000772 21078129 NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_provenance.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion wasDerivedFrom befree-2016 NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_provenance.
- NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_assertion wasGeneratedBy ECO_0000203 NP852456.RAu4f9-C9rO1t6VSgTvDSM8ZCMe8WALLHj6FTEBvp34P4130_provenance.